Skip to main content
. Author manuscript; available in PMC: 2020 Aug 24.
Published in final edited form as: Clin Cancer Res. 2020 Mar 9;26(14):3868–3880. doi: 10.1158/1078-0432.CCR-19-2335

Figure 6.

Figure 6.

Schematic of the molecular mechanism of the ascorbic acid anticancer effect. SDHB-low PCPGs exhibit an imbalance in intracellular iron levels due to abnormal activation of the HIF signaling pathway, which further leads to increased vulnerability to oxidative stress. Targeting of the ROS synthetic pathway with pharmacologic doses of ascorbic acid could be a valuable therapeutic strategy for cluster I PCPGs with complex II deficiencies.